Chemosensitivity testing of ovarian cancer using the histoculture drug response assay: Sensitivity to cisplatin and clinical response

S. Nakada, Daisuke Aoki, S. Ohie, M. Horiuchi, N. Suzuki, M. Kanasugi, N. Susumu, Y. Udagawa, S. Nozawa

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Despite cytoreductive surgery and chemotherapy, the prognosis of advanced ovarian cancer is still poor. Predicting the chemosensitivity of tumors might improve the outcome. Therefore, we investigated the clinical value of the histoculture drug response assay for ovarian cancer. Tumor specimens were cultured for 7 days on collagen gel sponge in medium containing cisplatin, and the 50% inhibitory concentration was determined by the 3-(4,5-dimethyl-2- thiazolyl)-2,5-diphenyltetrazolium bromide assay. Then the in vitro sensitivity to cisplatin was compared with the clinical response and survival. Apoptosis of tumor cells was also investigated. Among 173 ovarian cancer patients, 164 were evaluable by the assay, and 29 patients had measurable lesions for which the clinical response could be determined. The 5-year survival rate was significantly higher in patients with chemosensitive tumors than in those with chemoresistant tumors when the cutoff value was set at a 50% inhibitory concentration of 25 μg/mL and the accuracy of the assay was 82.8% (24/29). As chemosensitivity to cisplatin became greater, the number of apoptotic cells also increased. This chemosensitivity assay may help predict the clinical response to cisplatin-based chemotherapy, thus improving the survival of ovarian cancer patients.

Original languageEnglish
Pages (from-to)445-452
Number of pages8
JournalInternational Journal of Gynecological Cancer
Volume15
Issue number3
DOIs
Publication statusPublished - 2005 May

Fingerprint

Ovarian Neoplasms
Cisplatin
Pharmaceutical Preparations
Neoplasms
Inhibitory Concentration 50
Drug Therapy
Survival
Porifera
Bromides
Collagen
Survival Rate
Cell Count
Gels
Apoptosis

Keywords

  • Apoptosis
  • Chemosensitivity test
  • Cisplatin
  • Histoculture drug response assay
  • Ovarian cancer

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology
  • Cancer Research

Cite this

Chemosensitivity testing of ovarian cancer using the histoculture drug response assay : Sensitivity to cisplatin and clinical response. / Nakada, S.; Aoki, Daisuke; Ohie, S.; Horiuchi, M.; Suzuki, N.; Kanasugi, M.; Susumu, N.; Udagawa, Y.; Nozawa, S.

In: International Journal of Gynecological Cancer, Vol. 15, No. 3, 05.2005, p. 445-452.

Research output: Contribution to journalArticle

Nakada, S. ; Aoki, Daisuke ; Ohie, S. ; Horiuchi, M. ; Suzuki, N. ; Kanasugi, M. ; Susumu, N. ; Udagawa, Y. ; Nozawa, S. / Chemosensitivity testing of ovarian cancer using the histoculture drug response assay : Sensitivity to cisplatin and clinical response. In: International Journal of Gynecological Cancer. 2005 ; Vol. 15, No. 3. pp. 445-452.
@article{c97a1719902a415997bd257b7643e8e4,
title = "Chemosensitivity testing of ovarian cancer using the histoculture drug response assay: Sensitivity to cisplatin and clinical response",
abstract = "Despite cytoreductive surgery and chemotherapy, the prognosis of advanced ovarian cancer is still poor. Predicting the chemosensitivity of tumors might improve the outcome. Therefore, we investigated the clinical value of the histoculture drug response assay for ovarian cancer. Tumor specimens were cultured for 7 days on collagen gel sponge in medium containing cisplatin, and the 50{\%} inhibitory concentration was determined by the 3-(4,5-dimethyl-2- thiazolyl)-2,5-diphenyltetrazolium bromide assay. Then the in vitro sensitivity to cisplatin was compared with the clinical response and survival. Apoptosis of tumor cells was also investigated. Among 173 ovarian cancer patients, 164 were evaluable by the assay, and 29 patients had measurable lesions for which the clinical response could be determined. The 5-year survival rate was significantly higher in patients with chemosensitive tumors than in those with chemoresistant tumors when the cutoff value was set at a 50{\%} inhibitory concentration of 25 μg/mL and the accuracy of the assay was 82.8{\%} (24/29). As chemosensitivity to cisplatin became greater, the number of apoptotic cells also increased. This chemosensitivity assay may help predict the clinical response to cisplatin-based chemotherapy, thus improving the survival of ovarian cancer patients.",
keywords = "Apoptosis, Chemosensitivity test, Cisplatin, Histoculture drug response assay, Ovarian cancer",
author = "S. Nakada and Daisuke Aoki and S. Ohie and M. Horiuchi and N. Suzuki and M. Kanasugi and N. Susumu and Y. Udagawa and S. Nozawa",
year = "2005",
month = "5",
doi = "10.1111/j.1525-1438.2005.15307.x",
language = "English",
volume = "15",
pages = "445--452",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Chemosensitivity testing of ovarian cancer using the histoculture drug response assay

T2 - Sensitivity to cisplatin and clinical response

AU - Nakada, S.

AU - Aoki, Daisuke

AU - Ohie, S.

AU - Horiuchi, M.

AU - Suzuki, N.

AU - Kanasugi, M.

AU - Susumu, N.

AU - Udagawa, Y.

AU - Nozawa, S.

PY - 2005/5

Y1 - 2005/5

N2 - Despite cytoreductive surgery and chemotherapy, the prognosis of advanced ovarian cancer is still poor. Predicting the chemosensitivity of tumors might improve the outcome. Therefore, we investigated the clinical value of the histoculture drug response assay for ovarian cancer. Tumor specimens were cultured for 7 days on collagen gel sponge in medium containing cisplatin, and the 50% inhibitory concentration was determined by the 3-(4,5-dimethyl-2- thiazolyl)-2,5-diphenyltetrazolium bromide assay. Then the in vitro sensitivity to cisplatin was compared with the clinical response and survival. Apoptosis of tumor cells was also investigated. Among 173 ovarian cancer patients, 164 were evaluable by the assay, and 29 patients had measurable lesions for which the clinical response could be determined. The 5-year survival rate was significantly higher in patients with chemosensitive tumors than in those with chemoresistant tumors when the cutoff value was set at a 50% inhibitory concentration of 25 μg/mL and the accuracy of the assay was 82.8% (24/29). As chemosensitivity to cisplatin became greater, the number of apoptotic cells also increased. This chemosensitivity assay may help predict the clinical response to cisplatin-based chemotherapy, thus improving the survival of ovarian cancer patients.

AB - Despite cytoreductive surgery and chemotherapy, the prognosis of advanced ovarian cancer is still poor. Predicting the chemosensitivity of tumors might improve the outcome. Therefore, we investigated the clinical value of the histoculture drug response assay for ovarian cancer. Tumor specimens were cultured for 7 days on collagen gel sponge in medium containing cisplatin, and the 50% inhibitory concentration was determined by the 3-(4,5-dimethyl-2- thiazolyl)-2,5-diphenyltetrazolium bromide assay. Then the in vitro sensitivity to cisplatin was compared with the clinical response and survival. Apoptosis of tumor cells was also investigated. Among 173 ovarian cancer patients, 164 were evaluable by the assay, and 29 patients had measurable lesions for which the clinical response could be determined. The 5-year survival rate was significantly higher in patients with chemosensitive tumors than in those with chemoresistant tumors when the cutoff value was set at a 50% inhibitory concentration of 25 μg/mL and the accuracy of the assay was 82.8% (24/29). As chemosensitivity to cisplatin became greater, the number of apoptotic cells also increased. This chemosensitivity assay may help predict the clinical response to cisplatin-based chemotherapy, thus improving the survival of ovarian cancer patients.

KW - Apoptosis

KW - Chemosensitivity test

KW - Cisplatin

KW - Histoculture drug response assay

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=18944400161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18944400161&partnerID=8YFLogxK

U2 - 10.1111/j.1525-1438.2005.15307.x

DO - 10.1111/j.1525-1438.2005.15307.x

M3 - Article

C2 - 15882168

AN - SCOPUS:18944400161

VL - 15

SP - 445

EP - 452

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 3

ER -